All In Biotech

NDA 021454 · Endo Operations

Testim

Testosterone · Transdermal · Androgen

Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Oct 31, 2002

Approved uses

1

Original approval plus efficacy supplements

Registered trials

728

173 Phase 3, 64 recruiting

FAERS reports

22,552

13,806 serious, 1,106 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SECONDARY EXPOSURE TO TESTOSTERONE Virilization has been reported in children who were secondarily exposed to testosterone gel [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.2 )] . Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel [see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.1 )]. Healthcare providers should advise patients to strictly adhere to recommended instructions for use [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.1 ), and Patient Counseling Information ( 17 )]. WARNING: SECONDARY EXPOSURE TO TESTOSTERONE See full prescribing information for complete boxed warning. Virilization has been reported in children who were secondarily exposed to testosterone gel ( 5.1 , 6.2 ) Children should avoid contact with unwashed or unclothed application sites in men...

What it is approved for

From the label in effect Jul 15, 2025.

TESTIM is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of Use: Safety and efficacy of TESTIM in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Safety and efficacy of TESTIM in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Dosage and Administration ( 2 ) and Clinical Pharmacology ( 12.3 )] . TESTIM is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary Hypogonadism (Congenital or Acquired) ( 1 ) Hypogonadotropic Hypogonadism ( 1 ) Limitations of Use : Safety and efficacy of TESTIM in men with “age-related hypogonadism” have not been established. ( 1 ) Safety and efficacy of TESTIM in males less than 18...

Mechanism: Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis and scrotum; the development of male hair distribution, such as facial, pubic, chest and axillary hair; laryngeal enlargement; vocal cord thickening; and alterations in body musculature and fat distribution. Testosterone and DHT are necessary for the normal development of secondary sex characteristics....

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TESTIM · TESTOSTERONE 50MG/5GM PACKET · GEL, TRANSDERMAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Testosterone" as an intervention, any sponsor and status, largest first.

All 728 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,566
  • off label use1,302
  • fatigue1,272
  • pain1,223
  • myocardial infarction949
  • nausea925
  • anxiety923
  • headache858
  • deep vein thrombosis817
  • pulmonary embolism800
  • cerebrovascular accident783
  • asthenia678

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004170
2005138
2006147
2007176
2008210
2009284
2010351
2011396
2012956
2013429
2014787
20152,259
20161,925
20171,307
20181,442
20191,318
20201,254
20211,237
20221,450
20231,565
20241,651
20251,724
20261,376

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Testim (Testosterone)

2024 spending

$971K

Beneficiaries

245

882 claims

Per beneficiary

$3,964

$3.72 per unit

View as table
YearSpending
2020$1,342,568
2021$1,119,888
2022$1,118,835
2023$1,056,001
2024$971,129

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,506 on PubMed

Sponsor: Endo Operations

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.